| Objective:To estimate the curative effect of Qiliqiangxin capsule in treating coronary heart disease with chronic heart failure(CHF) and explore the mechanism through left ventricular ejection fraction(LVEF), left ventricular end-diastolic dimension(LVEDD) and amino-terminal pro-brain natriuretic peptide(NT-proBNP). To investigate these patients’ prognosis in6months and explore possible factors affecting prognosis.Methods:Patients with chronic heart failure due to coronary heart disease from The First Hospital of Hunan University of Chinese Medicine were randomly divided into Qiliqiangxin capsule treatment group(30cases) and conventional western medicine control group(30cases) with a treatment course of4weeks for both groups. The heart function and traditional Chinese medicine symdromes were observed. LVEF, LVEDD and NT-proBNP, as primary therapeutic indexes, were also observed and compared. Through telephone follow-up survey, cardiovascular events can be observed in6months after a treatment course. Test blood, urine, stool routine, liver function, renal function, electrolyte, etc, as safety indicators.Results:1. The total effective rates in treatment group and control group were 83.33%and73.33%respectively, there was a significant difference between the two groups.2. Compared with the integration of traditional Chinese medicine syndrome before treatment, it reduced prominently after treatment in each group. There was a remarkable difference between the two groups after treatment.3. The total effective rates for traditional Chinese medicine syndromes in treatment group and control group were86.67%and76.67%respectively, there was a significant difference between the two groups.4. Compared with the LVEF before treatment, it increased prominently after treatment in each group. There was a conspicuous difference between the two groups after treatment.5. Compared with the LVEDD before treatment, it reduced prominently after treatment in each group. There was no apparent difference between the two groups after treatment.6. Compared with the plasma NT-proBNP level before treatment, it reduced obviously after treatment in each group. There was a prominent difference between the two groups after treatment.7. The rates of cardiovascular events in treatment group and control group were35.71%and78.57%respectively in6months after a treatment course.8. There was no severe adverse reaction in the period of observation.Conclusions:1. Qiliqiangxin capsule can improve the patients’ heart function, symptoms and signs, and enhance clinical efficacy.2. Qiliqiangxin capsule can raise LVEF and reduce plasma NT-proBNP level, it can also strengthen cardiac contractive function and reduce the volume and pressure load to improve symptoms and signs.3. Qiliqiangxin capsule can also improve prognosis in6months. Plasma NT-proBNP level is superior to course, heart function and LVEF in evaluating prognosis.4. Qiliqiangxin capsule is safe in the treatment of chronic heart failure. |
PDF Full Text Request